Genetic testing for hereditary cancers provides critical insights for affected or at risk individuals and their families, enabling earlier risk identification and clinically actionable management strategies. CENTOGENE offers an extended hereditary oncology testing portfolio designed to support pan-cancer testing options for a comprehensive approach, cancer type -focused analysis for targeted insights, and preventive testing for unaffected individuals. With expertise in analyzing variants across more than 200 cancer-associated genes, CENTOGENE offers comprehensive testing solutions that supporting physicians on prognosis, diagnosis and treatment guidance for improved patient outcomes.
CentoCancerHereditary is a pan-cancer panel, covering genes associated with hereditary tumor predisposition syndromes. This panel is intended for individuals that have a personal and/or family history of cancer. Cancer types targeted in this panel comprise breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate, among others.
Learn more| TAT | 15 business days |
| Methods | NGS including CNV analysis |
CentoCancerHereditary Comprehensive is our most extensive pan-cancer panel covering more than 160 genes associated with hereditary tumor predisposition syndromes. This panel is intended for individuals that have a personal and/or family history of cancer. Cancer types targeted in this panel comprise breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate, among others.
Learn more| TAT | 15 business days |
| Methods | NGS including CNV analysis |
Cancer occurs in people of all ages, with some being nearly exclusively tied to childhood. CentoCancerHereditary Pediatric is our comprehensive solution to detect genes associated with pediatric cancer. The gene list has been carefully curated by internal and external experts to cover the most common forms of pediatric cancer, such as leukemia, malignant brain tumors, lymphomas, bone cancer, neuroblastoma, Wilms tumor, and rhabdomyosarcoma. Germline variants identified by this panel will help to define prognosis, differentiate patient/family risk, and guide treatment decisions. Spotting cancer early increases the chances of survival.
Learn more| TAT | 15 business days |
| Methods | NGS including CNV analysis |
Whole Genome Sequencing (WGS), offers the most comprehensive one-step solution with the highest diagnostic yield
Whole Exome Sequencing (WES) enables quicker and cost-effective diagnosis for patients with complex and unclear symptoms
Multiomics give a deeper understanding of human biological processes and acts as a unique and highly effective tool for early diagnosis
Create a diagnostic gene panel by selecting genes tailored to individual patient needs.
2 to >4.000
Selectable Genes
15 Business Days
TAT
Genome or Exome
Backbone
Our global network of customer support and experts guiding you every step of the way.
Send us a messageRegional Support
